Osteonecrosis of the jaw related to the use of bisphosphonates
Authors:
- Tim Van Den WyngaertTWTim Van Den Wyngaert
- Manon T HuizingMHManon T Huizing
- Jan B VermorkenJVJan B Vermorken
- 1 July 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 19 (4) , 315-322
Abstract
Osteonecrosis of the jaw associated with the use of potent nitrogen containing bisphosphonates is a new and challenging clinical entity with a high impact on quality of life. This review attempts to consolidate the rapidly expanding literature into practical guidelines and provides expert consensus for areas of uncertainty. Diagnostic criteria and a staging system for osteonecrosis of the jaw have been proposed, and histomorphologic analysis has confirmed osteonecrosis of the jaw as a proper disease, distinctively different from osteoradionecrosis. Various guidelines for the management of osteonecrosis of the jaw have been suggested and further retrospective research has provided new insights into its epidemiology. Osteonecrosis of the jaw is a distinct entity of uncertain origin that is increasingly being observed in patients treated with potent aminobisphosphonates, although the etiology is probably multifactorial. Recent data confirm the predisposition of multiple myeloma patients to develop osteonecrosis of the jaw. Although various treatment strategies have been reported, conservative management remains the mainstay of therapy.Keywords
This publication has 45 references indexed in Scilit:
- Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?Annals of Oncology, 2006
- Systematic Review: Bisphosphonates and Osteonecrosis of the JawsAnnals of Internal Medicine, 2006
- The role of bisphosphonates in breast and prostate cancers.Endocrine-Related Cancer, 2004
- Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 casesJournal of Oral and Maxillofacial Surgery, 2004
- The antineoplastic role of bisphosphonates: from basic research to clinical evidenceAnnals of Oncology, 2003
- Osteonecrosis of the jaws associated with cancer chemotherapyJournal of Oral and Maxillofacial Surgery, 2003
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Postradiation osteonecrosis of the mandibleOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 1997
- Osteonecrosis of the jaws: A complication of cancer chemotherapyHead & Neck Surgery, 1982